Physician profile
Todd Meadows
NPI 1982342325
$1,002.05
in general payments reported to CMS, 2019-2025
12 companies · $17.11 in 2025
The $17.11 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.16 · 2023: $435 · 2024: $529 · 2025: $17.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.89 | 2023-2024 | Relistor |
| Forte Bio-Pharma LLC | $162.71 | 2024 | Prolate, Nalocet |
| Pfizer INC. | $154.52 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $97.27 | 2022-2024 | Xtampza |
| Abbvie INC. | $69.28 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $63.47 | 2023 | Belsomra |
| Scilex Pharmaceuticals INC. | $55.06 | 2023-2025 | Ztlido |
| Almatica Pharma LLC | $36.44 | 2023 | Gralise |
| Averitas Pharma INC. | $29.59 | 2023 | Qutenza |
| Si-Bone, INC. | $26.14 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $26.05 | 2023 | Iovera, Zilretta |
| Dexcom, INC. | $19.63 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.